Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Liabilities and Shareholders Equity (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 34.19% to $1.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.7 billion through Dec 2025, up 15.4% year-over-year, with the annual reading at $1.5 billion for FY2025, 34.19% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $1.5 billion at Beam Therapeutics, up from $1.3 billion in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $1.5 billion in Q4 2025, with the low at $693.2 million in Q1 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $1.3 billion, with a median of $1.3 billion recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity soared 315.62% in 2021, then decreased 24.38% in 2024.
  • Over 5 years, Liabilities and Shareholders Equity stood at $1.5 billion in 2021, then fell by 9.0% to $1.3 billion in 2022, then increased by 8.79% to $1.5 billion in 2023, then fell by 24.38% to $1.1 billion in 2024, then surged by 34.19% to $1.5 billion in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $1.5 billion, $1.3 billion, and $1.4 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.